definiens: means inspections, audits or visits by Government Competent Authorities ; 1.19 means all intellectu al property rights, including ( without limitation ) patents, supplementary protection certificates, uti lity models, trademarks, database rights, rights in designs, copyrights and topography rights ( whether or not any of these rights are registered, and including applications and the right to apply for r egistration of any such rights ) and all ideas, discoveries, developments, improvements, enhancemen ts, adaptations, derivations, modifications, refinements, inventions, know- how, trade secrets, techniques and confidential inf ormation and other proprietary knowledge and information, and all righ ts ( including enforcement rights ) and forms of protection of a similar nature or having equivalent or similar effect to any of these which may subsist anywhere in the world, in each case for their full term, and together with any continuations, continuations -in -part, divisionals, renewals, reissues, reexaminatio ns, registrations or extensions ; 1.20 means the directors, officers, employees, contracto rs ( including consultants ) or professional advisers of the relevant Party or its Affiliates who are required, on a strict need to kn ow basis, in the course of their duties to receive and consider the Conf idential Information for the purpose of enabling the relevant Party to perform its oblig ations or exercise its rights under this Agreement or the Quality Agreement provided that such persons ar e under written obligations of confidence no less onerous than those contained herein at Section 8 which are imposed on the Receiving Party ; 1.21 shall have the meaning as defined in Section 9.1 ; 1.22 means the price for the Services as defined in Schedule 1 and in Schedule 2 ; 1.23 means the method of manufacture, processi ng, testing and packaging ( including labelling ) of the Product from the Raw Materials and Release o f Product which, pursuant to the Services, is to be produced by [COMPANY] for ImmunoCellular under thi s A greement ; 1.24 means ImmunoCellular autologous dendritic cell based cancer vaccine known as ; 1.25 means all Intellectual Property Rights owned or Controlled by [COMPANY] related to the purpose of this Agreement ; 1.26 has the meaning set out in Section 9.3 ; 1.27 means all technical and non - technical information known by [COMPANY] and which at the time of its first disclosure by Ph armaCe ll to ImmunoCellular or is used by [COMPANY] in the provision of Services, was neither ( i ) known to ImmunoCellular as demonstrated by written records existing at the time of such disclosure or ( ii ) freely available in the public domain ; 1.28 means the Services and deliverables descr ibed in the Schedules, the timelines therefor and the fees and costs thereof